TY - JOUR
T1 - Cognitive behavioral therapy for depression among adults in Japanese clinical settings
T2 - A single-group study
AU - Fujisawa, Daisuke
AU - Nakagawa, Atsuo
AU - Tajima, Miyuki
AU - Sado, Mitsuhiro
AU - Kikuchi, Toshiaki
AU - Hanaoka, Motomi
AU - Ono, Yutaka
N1 - Funding Information:
This study was supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Health, Labor and Welfare to YO. The authors express gratitude to Drs. Maho Iba, Yoshinobu Watanabe, Risa Eto, Yosuke Yamaguchi, and Katsuyo Henomatsu for conducting the therapy and Ms. Misaki Koshi for managing data.
PY - 2010
Y1 - 2010
N2 - Background. Empirical support for cognitive behavioral therapy (CBT) for treating Japanese patients with major depression is lacking, therefore, a feasibility study of CBT for depression in Japanese clinical settings is urgently required. Findings. A culturally adapted, 16-week manualized individual CBT program for Japanese patients with major depressive disorder was developed. A total of 27 patients with major depression were enrolled in a single-group study with the purpose of testing the feasibility of the program. Twenty six patients (96%) completed the study. The mean total score on the Beck Depression Inventory-II (BDI-II) for all patients (Intention-to-treat sample) improved from 32.6 to 11.7, with a mean change of 20.8 (95% confidence interval: 17.0 to 24.8). Within-group effect size at the endpoint assessment was 2.64 (Cohen's d). Twenty-one patients (77.7%) showed treatment response and 17 patients (63.0%) achieved remission at the end of the program. Significant improvement was observed in measurement of subjective and objective depression severity (assessed by BDI-II, Quick Inventory of Depressive Symptomatology-Self Rated, and Hamilton Depression Rating Scale), dysfunctional attitude (assessed by Dysfunctional Attitude Scale), global functioning (assessed by Global Assessment of Functioning of DSM-IV) and subjective well-being (assessed by WHO Subjective Well-being Inventory) (all p values < 0.001). Conclusions. Our manualized treatment comprised of a 16-week individual CBT program for major depression appears feasible and may achieve favorable treatment outcomes among Japanese patients with major depression. Further research involving a larger sample in a randomized, controlled trial design is warranted.
AB - Background. Empirical support for cognitive behavioral therapy (CBT) for treating Japanese patients with major depression is lacking, therefore, a feasibility study of CBT for depression in Japanese clinical settings is urgently required. Findings. A culturally adapted, 16-week manualized individual CBT program for Japanese patients with major depressive disorder was developed. A total of 27 patients with major depression were enrolled in a single-group study with the purpose of testing the feasibility of the program. Twenty six patients (96%) completed the study. The mean total score on the Beck Depression Inventory-II (BDI-II) for all patients (Intention-to-treat sample) improved from 32.6 to 11.7, with a mean change of 20.8 (95% confidence interval: 17.0 to 24.8). Within-group effect size at the endpoint assessment was 2.64 (Cohen's d). Twenty-one patients (77.7%) showed treatment response and 17 patients (63.0%) achieved remission at the end of the program. Significant improvement was observed in measurement of subjective and objective depression severity (assessed by BDI-II, Quick Inventory of Depressive Symptomatology-Self Rated, and Hamilton Depression Rating Scale), dysfunctional attitude (assessed by Dysfunctional Attitude Scale), global functioning (assessed by Global Assessment of Functioning of DSM-IV) and subjective well-being (assessed by WHO Subjective Well-being Inventory) (all p values < 0.001). Conclusions. Our manualized treatment comprised of a 16-week individual CBT program for major depression appears feasible and may achieve favorable treatment outcomes among Japanese patients with major depression. Further research involving a larger sample in a randomized, controlled trial design is warranted.
UR - http://www.scopus.com/inward/record.url?scp=77953827154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953827154&partnerID=8YFLogxK
U2 - 10.1186/1756-0500-3-160
DO - 10.1186/1756-0500-3-160
M3 - Article
C2 - 20529252
AN - SCOPUS:77953827154
SN - 1756-0500
VL - 3
JO - BMC Research Notes
JF - BMC Research Notes
M1 - 160
ER -